Biotech Startups

Lucence develops blood-based diagnostic tests for early cancer detection, hereditary and health risk assessment, treatment selection, and treatment response monitoring. Its liquid biopsy and tissue tests serve oncology patients and clinicians across multiple solid tumors and hematological cancers, available internationally and in the USA.

2 investors

Lucid Scientific develops Resipher, a technology for live, continuous, and noninvasive monitoring of cellular oxygen consumption rate to study cell metabolism. It serves researchers and scientists in cell biology and cell culture labs.

2 investors

Lumanity provides consulting services across strategy, evidence generation, stakeholder engagement, and technology and AI to support pharmaceutical and life sciences companies in bringing medicines to patients. It helps clients identify value inflection points to inform strategic decisions in drug development and commercialization.

2 investors

Lumi, developed by Reach Industries, builds technology to make scientists and laboratories more efficient in tackling research challenges. It serves the life sciences sector by automating routine lab tasks so scientists can focus on problem solving.

2 investors

Lumicell develops a fluorescence-guided intraoperative imaging technology, including its LUMISIGHT optical imaging agent, that illuminates cancerous tissue in the surgical cavity to help surgeons remove residual cancer during procedures such as lumpectomy. The platform is aimed at surgical oncology, starting with breast cancer, and its flagship product has received FDA approval.

2 investors

LUMICKS develops life science research tools that measure and apply forces around biological interactions to link structural and 'omics analysis to functional outcomes at the molecular and cellular level. Its instruments serve academic research, drug development, bioprocessing, and immuno-oncology markets.

2 investors

Luminary Therapeutics is a clinical-stage biotech developing allogeneic CAR-T cell therapies built on its Gamma 2.0+ platform to treat solid tumors, B-cell malignancies, and B-cell-mediated autoimmune diseases. The company uses a Dual CAR architecture and the TcBuster transposon system to address relapse, T cell exhaustion, and high manufacturing costs.

2 investors

LuminUltra provides microbial monitoring and testing solutions, including ATP field testing (Bugcount), qPCR diagnostics (Genecount), lab services, and a digital platform (Relay), to help industries detect and manage microbial risks. The company serves sectors such as food and beverage and water systems through products, research, and lab services.

2 investors

Lumos Pharma is a clinical-stage biopharmaceutical company developing therapies for rare diseases, with a lead candidate targeting Pediatric Growth Hormone Deficiency. It also pursues partnerships to in-license or acquire additional rare disease therapeutic candidates for development and commercialization.

2 investors

2 investors

Lycia Therapeutics is a biotechnology company developing LYTAC (Lysosomal Targeting Chimera) therapeutics that bind disease-causing extracellular and cell-surface proteins and route them into the cell's lysosome for degradation. Its targeted protein degradation platform, based on research from Carolyn Bertozzi's lab at Stanford, aims to address proteins previously considered undruggable.

2 investors

LymeAlert makes a lab-quality, at-home test that detects Lyme disease pathogens in the tick itself rather than the person or pet, returning results in under 30 minutes with app-based guidance on next steps. Developed at MIT, it is aimed at families, pets, and animals at risk of tick-borne illness.

2 investors

Lyric Bio develops tissue-engineered bioreactors that use a proprietary laser-printed cellular substrate to grow high-density human cells and produce human immunoglobulin (IvIg, ScIg) from a single donor. The company aims to reduce Ig therapy's dependence on blood and plasma donations and enable scalable manufacturing of complex donor-derived biologics.

2 investors

M2i is a French industrial group specializing in complex molecules and pheromone-based biocontrol products used to protect plants and crops as an alternative to conventional chemical pesticides. It also develops and manufactures active ingredients and intermediates for organic chemistry and life sciences, serving conventional and organic agriculture.

2 investors

Macomics is a drug discovery company developing therapies that target macrophage activity for diseases with limited or ineffective treatment options. It operates in the biotechnology and therapeutics sector.

2 investors

Macro Oceans develops seaweed-based (kelp) feedstocks and materials as a low-carbon alternative to petroleum-based chemicals and products, building a traceable seaweed supply chain with brand, technology, and grower partners.

2 investors

Maculaser develops a temperature-controlled retinal laser therapy to treat age-related macular degeneration, diabetic macular edema, and other retinal disorders by activating natural healing responses in eye cells. The company targets patients and healthcare providers globally for disease prevention and non-invasive retinal care.

2 investors

Magnet Biomedicine develops TrueGlue™, a molecular glue discovery platform for designing small molecule therapeutics that induce novel protein-protein interactions to treat cancer and immune disorders. The platform systematically identifies molecular glues capable of targeting historically difficult-to-drug proteins in precision medicine.

2 investors

Magnitude Biosciences provides a high-powered imaging assay that measures mitochondrial health and age-related morphological changes using C. elegans muscle tissue as a model system. The service helps researchers and pharmaceutical companies assess whether test compounds protect against age-associated mitochondrial degradation.

2 investors

Magnus Medical develops SAINT, an FDA-cleared, accelerated form of TMS (transcranial magnetic stimulation) therapy that uses precision neuromodulation to treat Major Depressive Disorder, including treatment-resistant depression, over a 5-day course. The noninvasive, non-drug treatment was developed at Stanford's Brain Stimulation Lab and is delivered to patients through verified clinical providers.

2 investors

Maman develops a microneedle-based medical device that replaces repeated self-injections and offers real-time hormonal monitoring using proprietary drug delivery technology. The company targets patients requiring frequent injections.

2 investors

Manifest Technologies develops the NAIO computational neuroimaging platform, which uses AI to integrate and analyze multi-modal neuroimaging data for biomarker discovery, target validation, and patient selection. It serves pharmaceutical CNS R&D and healthcare providers to support diagnosis and treatment of central nervous system disorders.

2 investors

MapLight Therapeutics is a biopharmaceutical company developing targeted treatments for central nervous system disorders through a platform designed to modulate neural circuits implicated in disease. The company's lead program is a fixed-dose combination targeting muscarinic receptors in development for schizophrenia and Alzheimer's disease psychosis.

2 investors

Marker Therapeutics develops novel T cell therapies, including adoptive T cell therapy approaches, for clinical applications in oncology and other diseases with high unmet need. The company focuses on advancing cell therapy candidates from research through clinical development.

2 investors